Brief: Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
04/12/2024 12:56
Dec 4 (Reuters) - Alterity Therapeutics Ltd ATH.AX :
* ALTERITY THERAPEUTICS COMPLETES LAST PATIENT VISIT IN
ATH434-201
PHASE 2 CLINICAL TRIAL IN EARLY-STAGE MULTIPLE SYSTEM ATROPHY
* ALTERITY THERAPEUTICS LTD - TOPLINE RESULTS FOR ATH434
PHASE 2
TRIAL EXPECTED EARLY 2025
Source text: ID:nGNX8jj8qj
Further company coverage: ATH.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital